GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Gross-Profit-to-Asset %

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Gross-Profit-to-Asset % : 0.00% (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Regencell Bioscience Holdings Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Regencell Bioscience Holdings's annualized Gross Profit for the quarter that ended in Jun. 2023 was $0.00 Mil. Regencell Bioscience Holdings's average Total Assets over the quarter that ended in Jun. 2023 was $14.09 Mil. Therefore, Regencell Bioscience Holdings's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 was 0.00%.


Regencell Bioscience Holdings Gross-Profit-to-Asset % Historical Data

The historical data trend for Regencell Bioscience Holdings's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Gross-Profit-to-Asset % Chart

Regencell Bioscience Holdings Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Gross-Profit-to-Asset %
- - - - -

Regencell Bioscience Holdings Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Regencell Bioscience Holdings's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regencell Bioscience Holdings's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's Gross-Profit-to-Asset % falls into.



Regencell Bioscience Holdings Gross-Profit-to-Asset % Calculation

Regencell Bioscience Holdings's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Jun. 2023 )/( (Total Assets (A: Jun. 2022 )+Total Assets (A: Jun. 2023 ))/ count )
=0/( (18.019+12.622)/ 2 )
=0/15.3205
=0.00 %

Regencell Bioscience Holdings's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Jun. 2023 )/( (Total Assets (Q: Dec. 2022 )+Total Assets (Q: Jun. 2023 ))/ count )
=0/( (15.548+12.622)/ 2 )
=0/14.085
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Regencell Bioscience Holdings Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Traded in Other Exchanges
N/A
Address
29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Headlines

From GuruFocus